TEVA - Teva and Viatris revives chance to dispute J&J's schizophrenia drug patent
2024-04-01 12:17:16 ET
NYSE: TEVA NASDAQ: VTRS NYSE: JNJMore on Johnson & Johnson, Teva Pharmaceutical, etc.
- Viatris Stock Is Still Worth Buying
- With Lawsuit And Medtech Tailwinds - Johnson & Johnson May Be Back
- Viatris Inc. (VTRS) R&D Event (Transcript)
- Teva and Launch Therapeutics collaborate for dual-action asthma rescue inhaler respiratory program
- J&J to settle Mississippi baby powder suit for $75M: report